To further add to this evidence, the aim of this study is to determine whether systemic inflammation is associated with the development of AD pathology, as indicated by plasma tau and Aβ38, 40 and 42 levels, in samples of midlife and older individuals without neurological disorders by applying a principal component analysis of a large number of inflammatory markers. The gene discussed is MAPT; the disease is Alzheimer disease.